Carlsbad, CA, Sept. 29, 2022 — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced its abstract was accepted for presentation at the American College of Surgeons (ACS) Clinical Congress 2022 being held October 16-20, 2022, in San Diego, CA.
Details of the abstract presentation are as follows:
Session: Colon and Rectal Surgery I
Title: LB1148 An Enteral Protease Inhibitor Significantly Accelerated the Return of Bowel Function after Bowel Resection
Presenter: Michael Dawson, M.D., Chief Medical Officer of Palisade Bio
Date & Time: Monday, October 17, 2022, 4:15 – 5:45 PM ET
The abstract is now available and can be accessed in the Congress Program Planner, here. The oral presentation will include new GI functional data sub-cuts from the highly statistically significant Phase 2 clinical study (NCT05056935) demonstrating LB1148 significantly accelerated the return of post-operative GI function in patients undergoing elective bowel resection. The data sub-cuts are based on laparoscopy and laparotomy with surgical characteristics including, right hemicolectomy, left hemicolectomy, sigmoid and low anterior resection (LAR) surgery. These patient groups are being included for presentation as they represent key patient populations being enrolled in the ongoing Phase 3 clinical study of LB1148 to accelerate the return of post-operative GI function in patients undergoing elective bowel resection.
About Palisade Bio
Palisade Bio is a late-stage biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company utilizes over three decades of research and established science that links the role of intestinal barrier biology and human disease to develop novel therapeutics that target and improve the integrity of the intestinal barrier.
The Company’s lead program, LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. In multiple clinical studies, LB1148 has demonstrated positive results in accelerating the time to return of postoperative bowel function, and the Company recently presented analysis that LB1148 reduced the incidence and severity of post-surgical abdominal adhesions. LB1148 is currently being evaluated in a pivotal Phase 3 clinical study for accelerating the return of postoperative bowel function and in a Phase 2 study for the prevention of post-surgical abdominal adhesions.
The Company believes that addressing the disruption of the intestinal barrier has the potential to fundamentally change the way diseases are treated and to establish new standards of patient care. For more information, please go to www.palisadebio.com.
Forward Looking Statements
This communication contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Palisade’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential to fundamentally change the way diseases are treated, the completion of enrollment for the Phase 3 study, the potential for the statistically significant Phase 3 data to allow for NDA approval, and the potential for LB1148 to establish the standard of care, if approved. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Palisade’s current expectations. Forward-looking statements involve risks and uncertainties. Palisade’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the company’s ability to advance its clinical programs, the uncertain and time-consuming regulatory approval process; the company’s ability to achieve additional financing to fund clinical development and the company’s ability to comply with the continued listing requirements for Nasdaq. Additional risks and uncertainties can be found in Palisade Bio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. Palisade expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Palisade’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Investor Relations Contact
JTC Team, LLC